Financhill
Back

Brooklyn ImmunoTherapeutics Quote, Financials, Valuation and Earnings

Sell
20

BTX
Brooklyn ImmunoTherapeutics

Last Price:
0.25
Seasonality Move:
10%

7 Day Trial

ALL ACCESS PASS

$ 7

Brooklyn ImmunoTherapeutics Price Quote

$0.25
+0.01 (+2.29%)
(Updated: September 30, 2022 at 3:40 PM ET)

Brooklyn ImmunoTherapeutics Key Stats

Sell
20
Brooklyn ImmunoTherapeutics (BTX) is a Sell

Day range:
$0.24 - $0.26
52-week range:
$0.21 - $10.10
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.97%

Volume:
293.8K
Avg. volume:
572.1K
1-year change:
-97.33%
Market cap:
$14.4M
Revenue:
$0
EPS:
$-2.09

How Much Does Brooklyn ImmunoTherapeutics Make?

Data Unavailable

Is Brooklyn ImmunoTherapeutics Growing As A Company?

Data Unavailable

Brooklyn ImmunoTherapeutics Stock Price Performance

What Is Brooklyn ImmunoTherapeutics 52-Week High & Low?

Brooklyn ImmunoTherapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Brooklyn ImmunoTherapeutics?

Is Brooklyn ImmunoTherapeutics Cash Flow Positive?

  • What Is BTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$22.7M
  • What Is Brooklyn ImmunoTherapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $15.1M
  • What Is Brooklyn ImmunoTherapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$23.1M

Brooklyn ImmunoTherapeutics Return On Invested Capital

Data Unavailable

Brooklyn ImmunoTherapeutics Earnings Date & Stock Price

Brooklyn ImmunoTherapeutics Competitors

Brooklyn ImmunoTherapeutics Dividend Yield

Data Unavailable

Brooklyn ImmunoTherapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 3.00
Upside from Last Price: 1127.5%

Major Shareholders

  • How many BTX shares are owned by institutional investors?
    17.3M BTX shares are owned by institutional investors
  • How many BTX shares are owned by insiders?
    7.2M BTX shares are owned by insiders